United States Patent 11,974,986: Scope, Claim Fencing, and US Patent Landscape for Pilocarpine Hydrochloride + Sodium Hyaluronate + HPMC (Distance Visual Acuity / Higher Order Aberrations)
Patent 11,974,986 claims a US method-of-improving vision effect tied to a specific ophthalmic drug composition and a defined pilocarpine hydrochloride (0.4%) plus sodium hyaluronate (0.1%) plus hydroxypropyl methylcellulose (0.8%) concentration package. The claim set is broad on route and patient phenotype while remaining composition-anchor strict on the concentration “about” values. Dependent claims narrow duration (up to 24/12/8 hours), stabilizer systems (sodium hydrogen sulphite and/or EDTA), dosing effect characterization (improves distance acuity and/or decreases higher order aberrations without harming night vision), and performance metrics (pupil size). This structure creates an enforceable “composition-in-method” fence, but also a design-around surface: change concentration package, move to a different mucoadhesive/viscosity system, or avoid the claimed higher order aberration/distance acuity improvement linkage.
What exactly does US Patent 11,974,986 claim: method-of-use for pilocarpine-based ophthalmic composition?
Short answer: It claims a method that uses a topically deliverable ophthalmic pharmaceutical composition (pilocarpine HCl 0.4% + sodium hyaluronate 0.1% + hydroxypropyl methylcellulose 0.8%) to improve distance visual acuity and/or reduce magnitude of higher order aberrations in a subject.
Claim 1 scope (independent claim) and what is required to infringe
Claim 1 elements (infringement requires all elements):
- A method (not a composition per se, though the method requires administering a specified composition).
- Administration to a subject of a therapeutically effective amount.
- Administering an ophthalmic pharmaceutical composition consisting of:
- Pilocarpine hydrochloride at about 0.4% (w/w or w/v)
- Sodium hyaluronate at about 0.1%
- Hydroxypropyl methylcellulose (HPMC) at about 0.8%
- One or more pharmaceutically acceptable carriers and/or excipients
- The therapeutic effect:
- Improves distance visual acuity and/or
- Decreases magnitude of higher order aberrations
- Therapeutic context:
- The claim is not limited to a particular disease label in the excerpt, but dependent claims tie to presbyopia/ocular surgery and spectacle/contact intolerance.
Composition anchor risk for generics and reformulators: because Claim 1 specifies the active and excipient identities and concentration “about” ranges, any challenge would likely turn on:
- whether the accused product’s “about” concentrations fall inside the patent-defined range as construed by the court; and
- whether the accused method reliably yields the claimed improvement outcome.
Claim 2: stabilizer selection narrows excipient carve-outs
Claim 2 limits carriers/excipients to include stabilizers selected from sodium hydrogen sulphite and/or EDTA (or mixtures).
- This is a dependent claim narrowing the excipient system.
- If an accused product uses a different antioxidant/chelator, it may avoid Claim 2 but can still infringe Claim 1 unless Claim 2 is needed to read on the accused product under its claim structure.
Claim 3, 6, 7: dosing duration and night vision constraint
- Claim 3: effective up to 24 hours and/or effective without adversely affecting night vision.
- Claim 6: effective up to 12 hours.
- Claim 7: effective up to 8 hours.
Enforcement implication:
- These time-based and night-vision limitations are additional features. They narrow the dependent claims; they do not narrow independent Claim 1 unless infringement is pursued under those dependent claims.
Claim 4: patient phenotype and treatment context is broad and inclusive
Claim 4 recites a non-exclusive set of subject characteristics, including:
- spectacle wearer who cannot or will not use progressive/bifocal lenses
- post-cataract surgery
- mono-focal or multifocal IOLs
- contact lens users who do not tolerate monovision or multifocal contact lenses
- higher order aberration after corneal surgery
- cannot tolerate spectacle prescription changes
- rapid spectacle prescription changes
- risk of falls when using progressive/bifocal lenses
This is a broad inclusion list. For infringement, the method must be practiced on a subject that meets one or more of these constraints depending on how dependent claim application is analyzed. It also helps the patentee argue the method is targeted to real-world visual function populations where distance acuity improvement is clinically relevant.
Claim 5: presbyopia correction without visual field reduction
Claim 5 adds:
- the composition corrects presbyopia
- without adversely reducing visual field
This adds a functional safety/efficacy limitation. Products that improve distance acuity but reduce visual field may try to avoid Claim 5.
Claim 8: uncorrected distance visual acuity is contemplated
Claim 8 specifies:
- distance visual acuity is uncorrected.
This helps distinguish against claims that depend on correction by glasses, or that rely on refraction changes.
Claim 9: route and delivery mode flexibility
Claim 9 states:
- administration is topical or by surgical intervention.
Most ophthalmic use will be topical, but this claim text leaves room for other delivery modes. For design-around, an accused product would need to avoid the claimed “administration” method structure, which is difficult if it is simply a topical eye drop.
Claim 10: “slow release composition” option
This claim introduces an alternative formulation type:
- slow release composition.
A fast-acting solution may still infringe Claim 1, but Claim 10 narrows.
Claim 11 and 12: dosage forms and “eye drop” form
- Claim 11: suspension, gel, ointment, injectable solution, spray, or eye drop.
- Claim 12: explicitly eye drop formulation.
Most commercial products in this space are drops. These claims reduce dosage-form design-around options.
Claim 14: objective measurement by pupil size change
Claim 14 limits method measurement:
- improvement/decrease measured by change in pupil size.
This matters for evidentiary proof. It also provides a hook for clinical endpoints in trials.
Claim 15: carriers/excipients include sodium chloride, pH agent, and water, plus stabilizers
Claim 15 specifies:
- stabilizers
- sodium chloride
- a pH agent
- water
This is narrow and likely not needed to infringe Claim 1, but it matters for dependent-claim strategy and for whether a court construes the composition as “consisting of” versus “comprising.” Your excerpt uses “consisting of” language in Claim 1, which is critical.
How does “consisting of” vs “comprising” affect infringement risk for formulations?
Claim 1 states the composition “consisting of” pilocarpine HCl, sodium hyaluronate, HPMC, and pharmaceutically acceptable carriers/excipients.
- “Consisting of” generally limits the specified essential components and permits only pharmaceutically acceptable carriers/excipients beyond them.
- This means a formulation that substitutes one of the essential components, even if it matches the functional effect, may not fall within Claim 1.
- It also means “additional active(s” could be excluded depending on how “carriers/excipients” and “consisting of” are construed.
Practical consequence:
- the most direct design-around is to alter the concentration package or replace one essential excipient class (for example, swap HPMC for a different cellulose derivative or polymer).
- a second design-around is to change the route or method outcome (avoid distance acuity improvement and/or higher order aberration magnitude decrease as a claimed intended use). In practice, method-of-use patents often still face the question of whether the prescribed use actually achieves the effect.
What therapeutic outcome is the claim trying to capture: distance acuity vs higher-order aberrations vs presbyopia?
The claim set triangulates around three clinical concepts:
- Distance visual acuity improvement (including uncorrected distance acuity)
- Lowering higher order aberration magnitude
- Presbyopia correction without reducing visual field
The synergy matters:
- pilocarpine is a miotic agent and can change pupil size, which can reduce certain optical aberrations by increasing effective depth of focus.
- the claim explicitly links to pupil size measurement (Claim 14).
- the inclusion of sodium hyaluronate and HPMC suggests a formulation intended for ocular comfort/retention and consistent drug delivery rather than a purely optical mechanism.
What does the claim structure imply for US patent scope: direct infringement, induced infringement, and Paragraph IV leverage?
Direct infringement (MDL-level practicalities)
To establish direct infringement, the plaintiff must prove:
- the defendant administered (or induced administration of) the accused ophthalmic composition; and
- the administration method achieves the claimed functional outcomes in a subject.
Because Claim 1 is a method, infringement can be enforced via prescribing and administering in clinical settings, including by entities that market and instruct use consistent with the patent’s method parameters.
Induced infringement risk
Marketing and labeling that instruct patients or prescribers to use the product for “distance visual acuity improvement” and/or “decreasing higher order aberrations” can support induced infringement theories even if the drug is generic or reformulated, provided the composition concentrations and excipient package still meet Claim 1.
Paragraph IV (ANDA) leverage
For ANDA filers, a Paragraph IV certification typically attacks the claims on:
- noninfringement (composition concentrations, excipient substitutions, no claimed method outcome in actual use);
- invalidity (anticipation/obviousness); and/or
- unenforceability (inequitable conduct) depending on file history.
The excerpted claim set indicates the most direct noninfringement routes are:
- reformulate outside the “about” ranges for pilocarpine/sodium hyaluronate/HPMC; and/or
- replace HPMC and/or sodium hyaluronate with different polymers that are not “HPMC” or “sodium hyaluronate,” respectively.
What is the likely patent landscape around this formulation and method in the US?
With only the claim text provided, the only firm conclusion is the internal landscape of this one patent’s claims: it spans formulation identity, concentration anchoring, and method outcomes. A full landscape across all related US patents for similar pilocarpine-based ophthalmic miotics and “presbyopia/distance acuity” outcomes requires the actual patent bibliographic data and the citation set.
What can be concluded from claim content alone
Even without seeing the citation tree, Claim 1 covers a narrow composition “core” and broadens by:
- allowing various acceptable carriers/excipients,
- allowing multiple subject categories,
- allowing multiple delivery modes (topical or surgical intervention),
- allowing multiple dosage forms.
This makes the patent structurally attractive to enforce against close reformulations that keep the same polymer/viscosity package. The broad dependent claim language lowers the odds that a close product avoids infringement on patient selection or dosing form.
Where the landscape pressure typically concentrates in this therapeutic space
In practice, US filings around this kind of profile often cluster in:
- pilocarpine ophthalmic compositions and their concentration ranges;
- compositions controlling ocular drug retention/viscosity (HPMC, hyaluronates);
- method-of-use for presbyopia, distance acuity, and optical aberrations via pupil modulation;
- formulation stability and preservative/stabilizer systems.
Patent 11,974,986 is positioned to read across these by merging formulation chemistry with a functional visual endpoint.
How strong is the patent estate for design-around resistance?
Based on Claim 1’s constraints, strength is driven by:
- Composition specificity: pilocarpine HCl 0.4% + sodium hyaluronate 0.1% + HPMC 0.8% “about” anchors.
- Outcome definition: improvement in distance visual acuity or decrease in higher order aberrations creates an additional hook beyond composition identity.
- Dependent claim broadening: route/dosage form/patient phenotype adds coverage.
Primary vulnerability:
- the “about” ranges are the main numerical escape valve, since reformulators can shift concentrations slightly.
- if an accused product’s clinical effect does not meet the “improves distance visual acuity or decreases higher order aberrations” threshold in practice, method-of-use infringement becomes harder to prove.
Key timelines: when does exclusivity typically expire and when do generics become feasible?
No exclusivity or expiration dates can be computed from the provided information alone. Patent term for US utility patents turns on filing date, statutory adjustments, and any terminal disclaimers. FDA exclusivity (if applicable) and Orange Book status (if listed) depend on the product NDA/BLA and patent listing details. Those data are not present in the prompt.
Key infringement scenarios (and the likely design-around angles)
Scenario A: near-match formulation, same polymer package
If a competitor’s eye drop uses pilocarpine HCl, sodium hyaluronate, and HPMC at concentrations that fall within the “about” ranges and administers therapeutically effective amounts, the product is at elevated risk for Claim 1 infringement, even if marketing focuses on comfort or miotic effects, provided the method outcome aligns.
Scenario B: swap HPMC for another cellulose polymer
Changing HPMC to another polymer (such as a different methylcellulose or carboxymethylcellulose) likely avoids the “HPMC at about 0.8%” limitation and can undercut Claim 1.
Scenario C: swap sodium hyaluronate for a different hyaluronate salt/derivative
If sodium hyaluronate is replaced with a different hyaluronate species or crosslinked derivative that is not “sodium hyaluronate,” the accused formulation may fall outside Claim 1.
Scenario D: keep concentrations, change stabilizer system
Switching away from sodium hydrogen sulphite/EDTA likely avoids Claim 2 and Claim 15, but not Claim 1 unless the “consisting of” limitation or excipient selection becomes central in claim construction.
Scenario E: avoid the claimed method outcome in labeling and use
A product may still infringe composition-based method claims if actual use improves distance acuity or reduces higher order aberrations. Label design and restricted indications can reduce induced infringement risk, but do not eliminate infringement if the claimed effect occurs.
Key Takeaways
- US 11,974,986 is a method-of-use patent that is composition-anchored. It requires administration of an ophthalmic formulation with pilocarpine HCl ~0.4% + sodium hyaluronate ~0.1% + HPMC ~0.8% plus excipients, and a functional outcome of improving distance visual acuity and/or decreasing higher order aberrations.
- Dependent claims broaden real-world coverage through multiple patient phenotypes, dosing duration (up to 24/12/8 hours), night-vision constraints, uncorrected distance acuity measurement, dosage form flexibility, and pupil size as an endpoint.
- Design-around is most feasible by changing the essential composition elements (especially swapping HPMC and/or sodium hyaluronate or shifting their “about” concentrations).
- The weakest practical area for enforcement is proof of the claimed visual outcome in actual clinical use, but composition-match products remain high-risk.
FAQs
- Can a generic pilocarpine eye drop avoid infringement of US 11,974,986 by changing only preservatives without changing HPMC or sodium hyaluronate?
- If a product matches pilocarpine/HPMC/hyaluronate concentrations, does absence of a “distance acuity” indication on labeling eliminate method-of-use infringement risk?
- How do the dependent claims on duration (24/12/8 hours) affect validity and infringement for a product with a different clinical residence time?
- What clinical endpoint strategies (pupil size vs wavefront higher order aberrations) align best with evidencing the claimed “higher order aberration” reduction?
- What formulation substitutions are most likely to fall outside “consisting of” when carriers/excipients are changed in the accused product?
References
- US Patent 11,974,986 (claims provided in prompt).
